Skip to main content

Table 1 Overview of cost and effect input data applied in the model

From: Early health economic evaluation of the future potential of next generation artificial vision systems for treating blindness in Germany

Parameter

Mean input value

Standard deviation

Distribution

Age at Therapy Start

51.1

5.3

Normal

Health State Costs ‘Visual Impaired’

€3,680

€368

Normal

Health State Costs ‘Blind’

€4,091

€409

Normal

Health State Costs ‘Death’

€0

€0

None

AVD Costs, first year (Base Case)

€85,000

€8,500

Normal

AVD Costs, first year (Scenario 1)

€55,000

€5,500

Normal

AVD Costs, first year (Scenario 2)

€70,000

€7,000

Normal

AVD Costs, first year (Scenario 3)

€100,000

€10,000

Normal

AVD Costs, first year (Scenario 4)

€115,000

€11,500

Normal

AVD Costs, annual follow-up

€1,500

€150

Normal

Health State Utility ‘Visual Impaired’

0.77

0,077

Normal

Health State Utility ‘Blind’

0.61

0.061

Normal

Health State Utility ‘Death’

0

0

None

Responder Rate AVD (Base Case)

62.5%

None

None

Responder Rate AVD (Scenario 1)

25%

None

None

Responder Rate AVD (Scenario 2)

50%

None

None

Responder Rate AVD (Scenario 3)

75%

None

None

Responder Rate AVD (Scenario 4)

100%

None

None

Discounting of Costs

3%

None

None

Discounting of Effects

3%

None

None